Results 181 to 190 of about 2,802,077 (293)

Dactolisib outperforms Rapamycin in potentiating apoptosis induced by XPO1, Bcl‐2 and Mcl‐1 blockade in preclinical glioblastoma models

FEBS Open Bio, EarlyView.
The PAM pathway and its impact on cellular metabolism. Color‐coded key symbols represent Rapamycin (R, orange, targeting mTOR) and Dactolisib (D, green, targeting PI3K/mTOR), indicating their sites of action. Created with BioRenders.com. Glioblastoma resists therapy through interconnected survival programs.
Kai Zhao, Leonie Meyer, Madita Braun, Katharina Otte, Celine Bitter, Maite Pawlik, Hartmann Raifer, Frederik Helmprobst, Axel Pagenstecher, Hans Urban, Michael C. Burger, Michael W. Ronellenfitsch, Joachim P. Steinbach, Jarmila Jedelská, Shamim Bagheri, Behrooz H. Yousefi, Pietro Di Fazio, Markus Luster, Andreas H. Mahnken, Andreas Neubauer, Andreas Burchert, Christopher Nimsky, Jörg W. Bartsch, Tillmann Rusch   +23 more
wiley   +1 more source

Hydrogel platforms for 3D cardiac tissue engineering and fibrotic disease modelling

FEBS Open Bio, EarlyView.
Hydrogel‐based cardiac tissue models are advancing our understanding of heart health and disease. By incorporating electrical conductivity, aligned structures, and tunable mechanical properties, these platforms better replicate the complex environment of native heart tissue.
Harrison Porritt, Annika Winbo, Jenny Malmström   +2 more
wiley   +1 more source

Aberration correction and complementary beam subtraction in light-sheet fluorescence microscopy. [PDF]

J Biomed Opt
Zhang Y, Yang R, Li X, Dan D, Yang Y, Liu Y, Li R, Qian J, Dai T, Kong L, Yu X, Yao B.   +11 more
europepmc   +1 more source

Early Clinical, Imaging, and Pathological Characteristics of SRPK3/TTN‐Digenic Myopathy

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective SRPK3/TTN‐digenic myopathy was recently established as a skeletal muscle myopathy caused by digenic inheritance. This study characterizes the early clinical presentation of SRPK3/TTN‐digenic myopathy in one previously reported and seven newly identified pediatric patients.
Rotem Orbach, Sandra Donkervoort, Carola Hedberg‐Oldfors, Giovanni Baranello, Dimah Saade, Precilla D'Souza, Ruchee Patel, Eva Michael, A. Reghan Foley, Diana Bharucha‐Goebel, S. Jin Haugland, Meghan McAnally, Omer Abdul Hamid, Katherine Chao, Ellen F. Macnamara, Alan H. Beggs, Anna Sarkozy, Juliane Mueller, Steven A. Moore, Richard S. Finkel, Cynthia J. Tifft, Francesco Muntoni, Anders Oldfors, Carsten G. Bönnemann   +23 more
wiley   +1 more source

Loop-Mediated Isothermal Amplification as an Alternative to Conventional Smear Microscopy in Pulmonary Tuberculosis. [PDF]

Cureus
Sharma S, Gupta P, Singhal A, Kour I, Kaur H, Gupta V, Singhal L.   +6 more
europepmc   +1 more source

Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin, Binbin Xue, Dewei Xie, Jia Li, Juyuan Pan, Lanbing Zhu, Qiaowen Tong, Jing Lin, Ruofan Zhu, Xu Zhang, Junhui Xia, Xiang Li   +11 more
wiley   +1 more source

Living Kidney Transplantation in a Patient With End-Stage Kidney Disease Due to Rare Juvenile Nail-Patella-Like Renal Disease Without <i>LMX1B</i> Mutation. [PDF]

Case Rep Transplant
Okabe T, Nakajima Y, Iwatsuki K, Maenosono R, Matsuda T, Tsuchida S, Hanamori T, Fujiwara Y, Nakamori K, Matsunaga T, Yoshikawa Y, Tsujino T, Matsumura H, Nomi H, Ashida A, Azuma H.   +15 more
europepmc   +1 more source

Plasma EV Proteomics Identifies ECM Remodeling and Inflammatory Proteins LUM and C7 as Candidate Biomarkers in FSHD

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Facioscapulohumeral muscular dystrophy (FSHD) is one of the most debilitating and common muscular dystrophies. Despite its severity, no approved therapy exists for FSHD patients. However, several therapeutic candidates are currently under development, and some have recently entered clinical trials, marking the need for reliable ...
Mustafa Bilal Bayazit, Chiranth K. Nagaraj, Jackson S. Newell, Kim Truc Nguyen, Xilal Y. Rima, Jacob Doon‐Ralls, Eduardo Reátegui, Jeffrey M. Statland, Rabi Tawil, Kevin M. Flanigan, Scott Q. Harper, Nizar Y. Saad   +11 more
wiley   +1 more source

Author Correction: Self-referencing ultrafast wide-field pump-probe microscopy. [PDF]

Nat Commun
Wu R, Zhang Y, Shahjahan M, Harel E.
europepmc   +1 more source

Characterizing Cutaneous α‐Synuclein Deposition and Seeding Activity in Parkinson's Disease Subtypes

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Cutaneous phosphorylated α‐synuclein (p‐syn) and α‐synuclein seeding activity are promising biomarkers for Parkinson's disease (PD), but their clinical value remains uncertain due to disease heterogeneity. This study evaluates these two biomarkers in PD patients to inform phenotype‐specific diagnosis and disease severity assessment ...
Yuting Jin, Tianyuan Yang, Minglei Liu, Haiyang Luo, Jing Yuan, Ke Zhang, Xinsheng Han, Jing Yang, Yuming Xu   +8 more
wiley   +1 more source